<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04427774</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI391A101</org_study_id>
    <nct_id>NCT04427774</nct_id>
  </id_info>
  <brief_title>A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor</brief_title>
  <official_title>A Phase Ib Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Surufatinib plus
      Sintilimab in Patients with Advanced Solid Tumor
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability assessed by monitoring frequency, duration, and severity of adverse events (AEs)</measure>
    <time_frame>Baseline through 30 days after end of treatment, up to approximately 24months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate in subjects with measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>Baseline and every 6 weeks through week 48, and then every 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">95</enrollment>
  <condition>Advanced or Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Surufatinib plus Sintilimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib plus Sintilimab</intervention_name>
    <description>Surufatinib will be given orally. Sintilimab will be given intravenously</description>
    <arm_group_label>Surufatinib plus Sintilimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Advanced or metastatic and recurrent cancer where an appropriate treatment option is
             not available

          2. Have measurable disease based on RECIST 1.1

          3. Life expectancy &gt; 12 weeks

          4. Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1

        Exclusion Criteria:

          1. Any therapy with anti-PD-1, or anti-PD-L1/l2 antibodies or anti-cytotoxic T lymphocyte
             associated antigen-4 (CTLA-4) antibody (or any other antibody acting on T cell
             costimulatory or checkpoint pathway) or fruquintinib treatment in previous;

          2. Prior receipt of Surufatinib

          3. History of any active autoimmune disease or autoimmune disease, including but not
             limited to interstitial pneumonia, uveitis, inflammatory bowel disease, hepatitis,
             pituitary inflammation, vasculitis, systemic lupus erythematosus, etc. (except
             patients with hypothyroidism that can be controlled only by hormone replacement
             therapy and patients with type I diabetes who only need insulin replacement therapy)

          4. History of gastrointestinal perforation and/or fistula, ileus, inflammatory bowel
             disease, or extensive enterotomy (partial colectomy or extensive enterotomy with
             chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea within 6
             months prior to first dosing

          5. Any life-threatening bleeding event or grade 3 or 4 bleeding requiring blood
             transfusion, endoscopy, or surgery with 3 months prior to dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jifeng Feng</last_name>
    <phone>025-83283597</phone>
    <email>fjif@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qing Zhao</last_name>
    <phone>025-83283415</phone>
    <email>ctc@jszlyy.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jiangsu Province</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

